Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Apolipoprotein E (APOE) Genotype Effects on Triglycerides and Blood Flow in the Human Brain

NCT04692441 · View on ClinicalTrials.gov ↗

Study Summary

High fat feeding (HFF) increases the risk of Alzheimer's disease (AD) but individuals who carry the AD risk gene E4 paradoxically improve after acute HFF. The investigators propose to further study this phenomenon with a clinical study to assess cerebral blood flow which can be measured by a technique called arterial spin labeling (ASL) on an MRI and is tightly related to brain metabolism.

Interventions

  • DIETARY_SUPPLEMENT Heavy Cream

Study Locations (1)

Washington

  • University of Washington Medical Center — Seattle

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2021-05-01
Est. Completion 2025-12-31
Phase NA

Sponsor

University of Washington

987 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04692441

The ClinicalTrials.gov registry entry for NCT04692441 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 987 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention — of which Heavy Cream is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04692441 reports 1 study location spanning 1 distinct geographic area — top geographies include Washington. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04692441 about?

NCT04692441 is a clinical study titled "Apolipoprotein E (APOE) Genotype Effects on Triglycerides and Blood Flow in the Human Brain". High fat feeding (HFF) increases the risk of Alzheimer's disease (AD) but individuals who carry the AD risk gene E4 paradoxically improve after acute HFF. The investigators propose to further study this phenomenon with a clinical study to assess cerebral blood flow which can be measured by a techniq...

What is the current status of trial NCT04692441?

This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2021-05-01. Estimated completion is 2025-12-31.

What conditions does trial NCT04692441 study?

This clinical trial studies the following conditions: Alzheimer Disease, Dementia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04692441?

The interventions under investigation include: Heavy Cream (DIETARY_SUPPLEMENT). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04692441?

This trial is sponsored by University of Washington, which has 987 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04692441 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial